Tissue | Expression Dynamics | Abbreviation |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:009006811 | Lung | MIAC | positive regulation of cell cycle process | 23/967 | 236/18723 | 2.65e-03 | 3.71e-02 | 23 |
GO:00512253 | Lung | MIAC | spindle assembly | 14/967 | 117/18723 | 2.84e-03 | 3.89e-02 | 14 |
GO:004578712 | Lung | MIAC | positive regulation of cell cycle | 28/967 | 313/18723 | 3.42e-03 | 4.43e-02 | 28 |
GO:190198711 | Lung | MIAC | regulation of cell cycle phase transition | 33/967 | 390/18723 | 3.79e-03 | 4.68e-02 | 33 |
GO:007121422 | Lung | MIAC | cellular response to abiotic stimulus | 29/967 | 331/18723 | 3.94e-03 | 4.78e-02 | 29 |
GO:010400422 | Lung | MIAC | cellular response to environmental stimulus | 29/967 | 331/18723 | 3.94e-03 | 4.78e-02 | 29 |
GO:001021222 | Lung | MIAC | response to ionizing radiation | 16/967 | 148/18723 | 4.15e-03 | 4.93e-02 | 16 |
GO:004592721 | Lung | MIAC | positive regulation of growth | 24/967 | 259/18723 | 4.15e-03 | 4.93e-02 | 24 |
GO:0006310 | Oral cavity | OSCC | DNA recombination | 147/7305 | 305/18723 | 6.33e-04 | 3.56e-03 | 147 |
GO:000632510 | Oral cavity | OSCC | chromatin organization | 190/7305 | 409/18723 | 1.17e-03 | 5.97e-03 | 190 |
GO:000632519 | Skin | cSCC | chromatin organization | 147/4864 | 409/18723 | 4.41e-06 | 6.52e-05 | 147 |
GO:000633812 | Skin | cSCC | chromatin remodeling | 94/4864 | 255/18723 | 7.58e-05 | 7.26e-04 | 94 |
GO:0016049112 | Thyroid | PTC | cell growth | 225/5968 | 482/18723 | 4.75e-12 | 2.07e-10 | 225 |
GO:000734619 | Thyroid | PTC | regulation of mitotic cell cycle | 212/5968 | 457/18723 | 4.03e-11 | 1.44e-09 | 212 |
GO:004477218 | Thyroid | PTC | mitotic cell cycle phase transition | 196/5968 | 424/18723 | 3.17e-10 | 1.02e-08 | 196 |
GO:0071214111 | Thyroid | PTC | cellular response to abiotic stimulus | 158/5968 | 331/18723 | 9.90e-10 | 2.89e-08 | 158 |
GO:0104004111 | Thyroid | PTC | cellular response to environmental stimulus | 158/5968 | 331/18723 | 9.90e-10 | 2.89e-08 | 158 |
GO:0001558111 | Thyroid | PTC | regulation of cell growth | 188/5968 | 414/18723 | 4.13e-09 | 1.09e-07 | 188 |
GO:000632520 | Thyroid | PTC | chromatin organization | 183/5968 | 409/18723 | 2.55e-08 | 5.70e-07 | 183 |
GO:001021219 | Thyroid | PTC | response to ionizing radiation | 79/5968 | 148/18723 | 4.56e-08 | 9.74e-07 | 79 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
INO80 | SNV | Missense_Mutation | rs747579178 | c.781C>A | p.Pro261Thr | p.P261T | Q9ULG1 | protein_coding | tolerated(0.24) | probably_damaging(0.994) | TCGA-A7-A0DB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
INO80 | SNV | Missense_Mutation | novel | c.1400G>T | p.Arg467Met | p.R467M | Q9ULG1 | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
INO80 | SNV | Missense_Mutation | | c.4322C>A | p.Ala1441Asp | p.A1441D | Q9ULG1 | protein_coding | tolerated(0.22) | benign(0.025) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
INO80 | SNV | Missense_Mutation | | c.4322N>T | p.Ala1441Val | p.A1441V | Q9ULG1 | protein_coding | tolerated(0.24) | benign(0) | TCGA-AN-A0XS-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
INO80 | SNV | Missense_Mutation | novel | c.3023N>G | p.Ser1008Cys | p.S1008C | Q9ULG1 | protein_coding | tolerated(0.07) | benign(0.174) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
INO80 | SNV | Missense_Mutation | | c.241N>T | p.Leu81Phe | p.L81F | Q9ULG1 | protein_coding | tolerated(0.16) | possibly_damaging(0.676) | TCGA-BH-A1FL-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
INO80 | SNV | Missense_Mutation | rs780868252 | c.934C>T | p.His312Tyr | p.H312Y | Q9ULG1 | protein_coding | tolerated(0.85) | benign(0.303) | TCGA-D8-A1XB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
INO80 | SNV | Missense_Mutation | | c.532A>G | p.Lys178Glu | p.K178E | Q9ULG1 | protein_coding | tolerated(0.52) | benign(0.074) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
INO80 | SNV | Missense_Mutation | novel | c.287N>T | p.Tyr96Phe | p.Y96F | Q9ULG1 | protein_coding | tolerated(0.61) | benign(0.031) | TCGA-LL-A73Z-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
INO80 | insertion | Frame_Shift_Ins | novel | c.2093_2094insGATTTTGAAGCCATTTATGCTGAGGAGAA | p.Ile698MetfsTer50 | p.I698Mfs*50 | Q9ULG1 | protein_coding | | | TCGA-B6-A0I8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |